Suven Pharmaceuticals Ltd.

NSE: SUVENPHAR | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Rocket
1137.5000 -11.20 (-0.98%)
NSE Apr 29, 2025 13:44 PM
Volume: 49,477
 

1137.50
-0.98%
Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting-Un-Audited Standalone And Consolidated Financial Results …
BSE India
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. November 08, 2022, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2022. We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2022 2) Limited Review Reports on the financial results as mentioned above and 3) Earnings Presentation of our company to investors We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M. This is for your information and record.
More from Suven Pharmaceuticals Ltd.
Recommended